Roivant Sciences to acquire Silicon Therapeutics to boost drug discovery capabilities

Roivant Sciences has agreed to acquire Silicon Therapeutics, a Boston-based drug design, research, and development company, for $450 million, in an all-share deal. The Swiss ... Read More